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ABSTRACT  
Insulin, Glibenclamide and Tolbutamide are some of the frequently used drugs 
for the most common metabolic disorders, diabetes mellitus. Along with 
hypoglycaemic drugs diabetic patient is exposed to variety of drugs. NSAIDs are 
one of the commonly used drugs in this metabolic syndrome. When a patient on 
hypoglycaemic drugs receives NSAIDs there are chances of drug interactions.  
This study was undertaken in the department of Pharmacology, GSVM medical 
college, Kanpur (UP) after approval by the institutional animal ethics committee 
to find out the interaction if any between Diclofenac and three hypoglycaemic 
drugs i.e. insulin, glibenclamide and tolbutamide.  
Young healthy rabbits were divided into six groups: five rabbits in each 
group. First group received Insulin 1 u/kg subcutaneously; second Glibenclamide 
0.05 mg/kg orally; third Tolbutamide 40 mg/kg orally; fourth Diclofenac 
1mg/kg orally and insulin 1mg/kg s.c. simultaneously; fifth glibenclamide 
0.05mg/kg orally at 0 hour and diclofenac 1mg/kg orally at 2 hours and sixth 
tolbutamide 40mg/kg orally at 0 hour and diclofenac 1mg/kg orally at 2 hours. 
Blood samples were taken at 0, 1, 2, 4 and 6 hours for blood sugar estimation.  
Mean blood sugar levels reduced significantly from their fasting levels when 
insulin, glibenclamide and tolbutamide were administered. However blood 
sugar levels did not showed any significant changes when diclofenac was 
administered along with insulin, glibenclamide and tolbutamide in comparison 
to when insulin, glibenclamide and tolbutamide were given alone. The results 
showed that diclofenac does not interact with insulin, glibenclamide and 
tolbutamide on blood sugar levels in rabbits. 
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Introduction 
Diabetes mellitus (DM) affects 
approximately 5 to 8% of the human 
population. DM has been a mass killer on 
globe for quite a long time. [1] In recent 
years, developed nations have witnessed an 
explosive increase in the prevalence of DM 
predominantly related to lifestyle changes 
and the resulting increase in prevalence of 
obesity. The metabolic consequences of 
prolonged hyperglycemia and dyslipidemia, 
including accelerated atherosclerosis, 
chronic kidney disease, and blindness, pose 
an enormous burden on patients with DM 
and on the public health system. DM affects 
multiple organ systems and makes the 
patient prone for infections. Because of 
above mentioned reasons a significant 
number of patients of DM are on 
polypharmacy. However polypharmacy 
carries risks of drug interactions and 
adverse drug reactions. [2] DM consists of a 
group of syndromes characterized by 
altered metabolism of carbohydrate, 
proteins and lipids: and an increased risk of 
complications from vascular disease. [3] It 
can be prevented upto some extent by 
lifestyle modifications especially in the 
persons where genetic predisposition is 
absent. [4] Hyperglycemia is a common end 
point for all types of DM and is the 
parameter that is measured to evaluate and 
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manage the efficacy of pharmacotherapy. 
Insulin, Glibenclamide and Tolbutamide are 
few of the commonly used drugs for 
diabetes mellitus. [5] Inflammation is the 
dynamic process by which living tissues 
react to injury. Inflammation characterized 
by pain and swelling is a protective reaction 
of the vascularized tissue to injury, intended 
to eliminate the cause of cell injury. [6] 
Acute inflammation is characterized by 5 
cardinal signs: redness, heat, swelling, pain 
and loss of function. [7] The process is 
related to vascular and connective tissues. 
Drugs to treat inflammation and 
immune reactions are very extensively used 
in medical practice. [8] The nonsteroidal 
anti-inflammatory drugs (NSAIDs) have a 
variety of clinical uses as antipyretics, 
analgesics, and anti-inflammatory agents. 
As diabetic patients mostly have to be 
treated for their whole life; they receive 
various drugs including NSAIDs. A significant 
number of drug interactions are common 
with number of NSAIDs.                                                                                         
It has been observed that NSAIDs in 
therapeutic and toxic doses have effects on 
blood sugar levels. [9] Ibuprofen drops may 
affect blood sugar levels. [10] Since 
sulfonylureas are highly bound to plasma 
proteins and are extensively metabolized by 
microsomal enzymes, coadministration of 
drugs capable of displacing them from their 
protein binding sites or inhibiting their 
metabolism (e.g., sulfonamide 
antibacterials, propranolol, salicylates, 
phenylbutazone, chloramphenicol, 
probenecid, and alcohol) also may 
potentiate hypoglycemia. [11] The aim of this 
study was to assess the effect of interaction 
of diclofenac with insulin, glibenclamide 
and tolbutamide on blood sugar levels in 
rabbits.   
 
Material and Methods 
This study was undertaken in the 
Department of Pharmacology, G.S.V.M. 
Medical College, Kanpur, U.P. after 
obtaining the approval from Institutional 
animal’s ethics committee.  This study was 
conducted on young healthy albino rabbits 
of both sexes weighing 1-1.6 Kg. All the 
animals were maintained under 
recommended animal house conditions. 
Rabbits were divided into six groups. Five 
rabbits were placed in each group. Rabbits 
were fasted overnight. In the morning the 
following drugs were given.               
                                              
Group 1: Rabbits of this group received 
insulin 1 unit/kg subcutaneously.  
Group 2: Rabbits of this group received 
glibenclamide 0.05 mg/kg orally.  
Group 3: Rabbits of this group received 
tolbutamide   40 mg/kg orally. 
Group 4: Rabbits of this group received 
insulin 1 unit/kg subcutaneously and 
diclofenac 1 mg/kg orally simultaneously. 
Group 5: Rabbits of this group received 
glibenclamide 0.05 mg/kg orally at 0 hour 
and diclofenac 1 mg/kg orally at 2 hours. 
Group 6: Rabbits of this group received 
tolbutamide 40 mg/kg orally at 0 hour and 
diclofenac 1mg/kg orally at 2hours. 
 
Blood samples were taken at 0, 1, 2, 
4 and 6 hours. All Blood samples were 
collected from marginal vein of pinna under 
aseptic conditions. Immediately after taking 
the last blood sample rabbits received 
standard animal diet. Water was available 
ad-libidum to rabbits during the study. 
Estimation of blood sugar was done by 
using glucose oxidase-peroxidase method. 
Monozyme diagnostic reagent kit (CODE 
NO. k2020) was used. Due to specificity of 
enzymes, the enzymatic method is the most 
accurate. Enzymes used in this method are 
glucose oxidase and peroxide. 
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Glucose is oxidized by glucose oxidase to 
gluconic acid and Hydrogen peroxide. [12]                                                      
       
                               Glucose oxidase  
Glucose+H2O+O2 ------------- Gluconic acid 
+ H2O2 
Hydrogen peroxide thus formed is broken 
down to water and nascent oxygen by 
glucose peroxidase. Oxygen acceptor 
accepts oxygen and forms quinolamine 
compound which gives a red colour. The red 
colour so developed is measured at 510-590 
nm and is directly proportional to glucose 
concentration. Glucose oxidase / 
peroxidase method used currently is 
relatively free from interference. There is 
no interference from urates, creatinine, 
glutathione and heamoglobin. 
Equipment: 
For the estimation of blood glucose levels, 
“photoelectric colorimeter” having 510 nm-
590 nm filters was used. 
Calculation: 
      Absorbance of test 
Glucose(mg/dl)= --------------------------- x100   
.                           Absorbance of standard 
Statistical analysis: 
The results obtained were analyzed by using 
Student’s t test and “p” value less than 0.05 
and 0.01 were considered significant and 
highly significant respectively. 
 
Results 
The blood sugar levels at zero hour served 
as control in all the six groups. (Table 1) The 
insulin treated group (1st group) showed 
highly significant fall in blood sugar levels 
till 2 hours; this effect persisted 4 hours 
although it became significant from highly 
significant. At the end of 6 hours the fall in 
blood sugar levels became insignificant. 
(Table 1) The glibenclamide treated group 
(2nd group) showed highly significant fall in 
blood sugar levels at 2 hours. This effect 
persisted till 6 hours. (Table 1) The 
tolbutamide treated group (3rd group) did 
not show significant fall in blood sugar 
levels till 1 hour; however after 2 hours this 
group showed highly significant fall in blood 
sugar levels. This effect persisted till 4 
hours; than fall became significant. (Table 1)  
 
Table 1: Means blood sugar levels following administration of insulin (1 unit/kg s.c.), 
glibenclamide (0.05 mg/kg p.o.) and tolbutamide (40 mg/kg p.o.) in overnight fasted rabbits. 
(n=5)       
Drugs 
 
  0hour  









Insulin 108.72±6.35 65.64±3.81** 61.26±4.12** 99.38±2.56* 104.34±2.67 
Glibenclamide 111.26±5.06 94.36±3.02** 90.02±8.05** 69.40±7.06** 71.88±4.90** 
Tolbutamide 111.24±6.46 104.36±6.73 86.88±2.58** 63.76±4.17** 71.26±4.61* 
*Significant (p<0.05) **Highly Significant (p<0.01)
 
The insulin + diclofenac treated group (4th 
group) showed insignificant fall in blood 
sugar levels from 1 hour till 6 hours in 
comparison to insulin treated group. (Table 
2) The glibenclamide + diclofenac treated 
group (5th group) showed insignificant fall in 
blood sugar levels from 1 hour till 6 hours in 
comparison to glibenclamide treated group. 
(Table 3) The tolbutamide + diclofenac 
treated (6th group) showed insignificant fall 
in blood sugar levels from 1 hour till 6 hours 
in comparison to tolbutamide treated 
group. (Table 4) 
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Table 2: Modification of insulin induced changes in blood sugar levels by Diclofenac (n=5) 














65.00±3.42 60.02±3.39 100.00±3.08 103.74±5.12 
“p” value >0.05 >0.05 >0.05 >0.05 
 
 
TABLE 3: Modification of glibenclamide induced changes in blood sugar levels by Diclofenac 
(n=5) 














94.36±6.75 88.76±7.17 71.86±6.23 75.64±8.67 
“p” value >0.05 >0.05 >0.05 >0.05 
 
 
















104.36±7.80 86.24±4.74 63.14±6.73 73.12±5.20 
“p” value >0.05 >0.05 >0.05 >0.05 
 
Discussion 
Patients of DM specifically non-insulin 
dependent diabetes mellitus are tried to be 
managed by diet and exercise initially13. 
Some patients can be managed by this 
approach; however significant number of 
patients requires hypoglycaemic drugs. 
Once pharmacotherapy is started generally 
it has to be continued for a very long 
duration including life time of the patient14. 
 DM is an autoimmune syndrome. The 
treatment should not only consider 
lowering the blood glucose level but also 
should focus on the correction of any 
associated coronary vascular disease risk 
factors such as smoking, hyperlipidemias, 
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and obesity as well as monitoring of blood 
pressure . Besides the drugs required for 
hyperlipidemias and hypertension the 
diabetic patients are exposed to many other 
drugs i.e. drugs for erectile dysfunction, 
antibiotics and NSAIDs.  
It means many DM patients are on 
polypharmacy. This creates increased 
chances of drug interactions. Drug 
interactions affects by two ways i.e. 
increasing/decreasing the pharmacological 
effects of hypoglycaemic or interacting drug 
and increased/decreased levels of blood 
sugar. Significant drug interactions and 
patient harm that results from them are 
common concerns in clinical practice. One 
study showed that although drug 
interactions account for only 3.8% of 
emergency room visits, the patients 
affected by them usually have to be 
admitted to the hospital15. However it is not 
only the drug-drug interactions; the drug-
disease interactions are also very common 
in diabetics16.  
NSAIDs are known to have 
interactions with a number of drugs; 
Sulfonylureas are one of those drugs. Most 
of these drug interactions are because of 
displacement of the drugs from plasma 
protein binding sites. Based on the above 
facts we carried out this study. We tried to 
find out whether diclofenac has any 
influence on the hypoglycaemic effects 
produced by insulin, glibenclamide and 
tolbutamide. Insulin, glibenclamide and 
tolbutamide when given alone produced 
significant hypoglycaemic effect as 
expected. When Diclofenac was given with 
insulin, glibenclamide and tolbutamide 
there was significant fall in blood sugar 
levels. This means that hypoglycaemic 
effect of insulin, glibenclamide and 
tolbutamide persisted with Diclofenac. On 
comparison of hypoglycaemic effects 
produced by insulin and insulin + diclofenac 
(Table 2); glibenclamide and glibenclamide 
+ diclofenac (Table 3) and tolbutamide and 
tolbutamide + diclofenac (Table 4) it was 
found that diclofenac did not have any 
influence on the hypoglycaemic effects of 
insulin, glibenclamide and tolbutamide. The 
non-interaction of diclofenac with insulin, 
glibenclamide and tolbutamide will occur or 
not in human beings is the topic of further 
research.  
Diclofenac does not interact with 
Insulin, Glibenclamide and Tolbutamide on 
blood sugar levels in rabbits. Whether these 
findings are true to human beings or not is 
the subject of further research. 
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